Abstract
Some studies have found that donor-recipient killer cell immunoglobulin g-like receptor (KIRs) ligand compatibility or incompatibility influences the prognosis of hematopoietic stem cell transplantation between unrelated individuals, although the conclusions of these studies are controversial. We performed a meta-analysis concerning unrelated donor transplantation with donor-recipient KIRs compatible or incompatible. A higher 5-year overall survival rate (odds ratio [OR] = 1.93, 95% confidence interval [CI] = 1.03 to 3.61, P = .04) was found in KIR-mismatched transplantations; however, no difference was observed in the incidence of grade 2 to 4 acute graft-vs-host disease (OR = 0.94, 95% CI = 0.71 to 1.24, P = .64), 5-year relapse rate (OR = 1.05, CI = 0.75 to 1.47, P = .77), or transplantation/treatment-related mortality (OR = 0.61, CI = 0.15 to 2.51, P = .50). Our meta-analysis confirmed that incompatibility in KIR ligands favors 5-year overall survival rate but has no effect on the incidence of grade 2 to 4 acute graft-vs-host disease, relapse, or transplantation/treatment-related mortality.
References
Jan 16, 1998·Immunity·M UhrbergP Parham
Feb 17, 1998·European Journal of Immunology·R BiassoniA Moretta
Mar 16, 2002·Science·Loredana RuggeriAndrea Velardi
Oct 24, 2002·Blood·Stella M DaviesBruce R Blazar
Apr 12, 2003·Blood·Sebastian GiebelJerzy Holowiecki
Mar 3, 2004·Tissue Antigens·A BisharaS Slavin
Oct 14, 2004·Transplantation·Marie SchafferMats Remberger
Nov 13, 2004·Blood·Daniela PendeLorenzo Moretta
May 18, 2005·Tissue Antigens·D De SantisF T Christiansen
Sep 1, 2005·Blood·Sarah CooleyJeffrey S Miller
Mar 1, 2006·Transplantation Proceedings·S GiebelJ Holowiecki
Jul 26, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sherif S FaragUNKNOWN KIR Study Group, Center for International Blood and Marrow Transplantation Research
Aug 19, 2006·Seminars in Cancer Biology·Loredana RuggeriAndrea Velardi
Feb 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yasuo MorishimaUNKNOWN Japan Marrow Donor Program
Feb 24, 2007·Blood·Jeffery S MillerDaniel J Weisdorf
Mar 21, 2007·Blood·Loredana RuggeriAndrea Velardi
Jun 23, 2007·Transplant Immunology·J SivulaH Turpeinen
Oct 30, 2007·Blood Cells, Molecules & Diseases·Loredana RuggeriAndrea Velardi
Dec 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Toshio YabeUNKNOWN Japan Marrow Donor Program
Aug 5, 2008·Current Opinion in Immunology·Andrea Velardi
Oct 24, 2008·Blood·Daniela PendeAlessandro Moretta
Apr 14, 2009·Bone Marrow Transplantation·R CrocchioloA Bacigalupo
Nov 12, 2009·Blood·Cyril FauriatJakob Michaëlsson
Feb 4, 2010·Blood·Jeffrey M VenstromKatharine C Hsu
Nov 30, 2010·Bone Marrow Transplantation·L BühlmannM Stern
Jul 28, 2011·Blood·Antonio CurtiRoberto M Lemoli
Dec 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WeisdorfJeffrey Miller
Aug 28, 2012·Immunogenetics·Johannes C FischerMarkus Uhrberg
Aug 31, 2012·The New England Journal of Medicine·Jeffrey M VenstromKatharine C Hsu
Citations
Sep 16, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiaojing BaoJun He
Jun 25, 2016·PloS One·Rehan Mujeeb FaridiFaisal Masood Khan
Sep 30, 2016·World Journal of Transplantation·Hisham A EdinurNor F Che Mat
Jun 27, 2018·HLA : Immune Response Genetics·S L HeatleyA G Brooks
Jan 31, 2020·HLA : Immune Response Genetics·Paul A Wright
Jul 29, 2017·Frontiers in Immunology·Carmen Martínez-LosadaConcha Herrera
Nov 7, 2017·Expert Opinion on Biological Therapy·Katalin Balassa, Vanderson Rocha
Nov 13, 2020·Frontiers in Immunology·Benjamin H GoldensonDan S Kaufman